...
首页> 外文期刊>EXCLI Journal >DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification
【24h】

DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification

机译:使用甲基化特异性多重连接依赖探针扩增技术将DNA甲基化评估作为浸润性乳腺癌的预后因素

获取原文
           

摘要

DNA methylation of promoter regions is a common molecular mechanism for inactivation of tumor suppressorgenes that participates in carcinogenesis. Determining the methylation status of genes in cancer and their associationwith clinical features play an essential role in early diagnosis, prognosis and determine appropriate treatmentfor patients. The purpose of the present study was to evaluate the methylation of tumor suppressor genes inpatients with invasive ductal carcinoma (IDC). Furthermore, we evaluated the association between clinical parametersand DNA methylation as a biomarker in diagnostic IDC patients. The methylation-specific multiplexligation dependent probe amplification (MS-MLPA) assay was used to analyze the methylation profile of 24genes in formalin-fixed paraffin embedded (FFPE) tissue samples from 75 patients with IDC. Each of the patientsshowed a distinctive methylation profile. We observed higher methylation in the RASSF1 (48 %), CDH13(44 %) and GSTP1 (36 %) genes. Some of the methylated genes were associated with clinical features. Methylationof GSTP1 (P=0.028) and RASSF1 (P=0.012) were related with lymph node metastasis. Methylation ofGSTP1 (P=0.005) was associated with high histological grade. Moreover, concurrent methylation of GSTP1 andCDH13 was observed in IDC patients (p<0.001). Hierarchical cluster analysis based on the methylation profilerevealed two main clusters of patients, the highly methylated cluster being significantly associated with highhistological grade and lymph node metastasis. The results of this study indicate that the methylation status ofRASSF1 and CDH13 and GSTP1 can be a prognostic marker to better management of IDC patients.
机译:启动子区域的DNA甲基化是使参与肿瘤发生的抑癌基因失活的常见分子机制。确定癌症中基因的甲基化状态及其与临床特征的关系,对早期诊断,预后和确定适合患者的治疗起着至关重要的作用。本研究的目的是评估侵袭性导管癌(IDC)患者的肿瘤抑制基因的甲基化。此外,我们评估了临床参数与DNA甲基化之间的关联,作为诊断性IDC患者的生物标志物。甲基化特异性多重连接依赖性探针扩增(MS-MLPA)分析用于分析来自75例IDC患者的福尔马林固定石蜡包埋(FFPE)组织样本中24个基因的甲基化分布。每位患者均表现出独特的甲基化特征。我们在RASSF1(48%),CDH13(44%)和GSTP1(36%)基因中观察到更高的甲基化。一些甲基化基因与临床特征有关。 GSTP1(P = 0.028)和RASSF1(P = 0.012)的甲基化与淋巴结转移有关。 GSTP1的甲基化(P = 0.005)与组织学等级高有关。此外,在IDC患者中观察到了GSTP1和CDH13的同时甲基化(p <0.001)。基于甲基化谱的层次聚类分析揭示了两个主要的患者聚类,高度甲基化的聚类与高组织学等级和淋巴结转移显着相关。这项研究的结果表明,RASSF1,CDH13和GSTP1的甲基化状态可以作为更好地管理IDC患者的预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号